Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress

Nagasaki University, Nagasaki, Nagasaki, Japan
Rheumatology (Impact Factor: 4.44). 06/2007; 46(5):790-5. DOI: 10.1093/rheumatology/kem010
Source: PubMed

ABSTRACT To determine the prevalence and clinical correlation of autoantibody to peroxiredoxin (Prx) I, an antioxidant enzyme, in patients with systemic sclerosis (SSc).
Serum samples from SSc patients (n = 70) and healthy controls (n = 23) were examined by ELISA using human recombinant Prx I. The presence of anti-Prx I antibody was further evaluated by immunoblotting analysis. To determine the functional relevance of anti-Prx I antibody in vivo, we assessed whether anti-Prx I antibody was able to inhibit Prx I enzymatic activity using yeast thioredoxin reductase system.
IgG anti-Prx I antibody levels in SSc patients were significantly higher than healthy controls and this autoantibody was detected in 33% of SSc patients. The presence of IgG anti-Prx I antibody was associated with longer disease duration, more frequent presence of pulmonary fibrosis, heart involvement, and anti-topoisomerase I antibody and increased levels of serum immunoglobulin and erythrocyte sedimentation rates. IgG anti-Prx I antibody levels also correlated positively with renal vascular damage and negatively with pulmonary function tests. Furthermore, anti-Prx I antibody levels correlated positively with serum levels of 8-isoprostane, a marker of oxidative stress. Immunoblotting analysis confirmed the presence of anti-Prx I antibody. Remarkably, Prx I enzymatic activity was inhibited by IgG isolated from SSc sera containing IgG anti-Prx I antibody.
These results suggest that elevated IgG anti-Prx I autoantibody is associated with the disease severity of SSc and that anti-PrxI antibody may enhance the oxidative stress by inhibiting Prx I enzymatic activity.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This is a review of autoantibodies described in systemic sclerosis with an emphasis on recently published studies. In the past, most, if not all of the discussion on this topic focused on antinuclear antibodies, but it is now appreciated that autoantibodies to cytoplasmic, cell surface, intercellular and plasma components are also important in the context of systemic sclerosis. A number of recent studies have highlighted the disease associations of autoantibodies and the potential pathogenic role of the more traditional autoantibodies, such as antitopoisomerase I and anticentromere antibodies. The recent identification of autoantibodies directed to the platelet-derived growth factor receptor is of particular interest because of its possible association with the pathogenesis of systemic sclerosis. Autoantibodies in systemic sclerosis are associated with demographic, diagnostic, pathological, and prognostic features of the disease. Emerging research on the pathogenic roles of newer autoantibodies provides valuable insights into disease pathogenesis and potential therapeutic targets.
    Current Opinion in Rheumatology 12/2007; 19(6):580-91. DOI:10.1097/BOR.0b013e3282e7d8f9 · 5.07 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The currently available tests for the diagnosis of cystic echinococcosis (CE), enzyme-linked immunosorbent assay (ELISA), and immunoblotting (IB) lack sensitivity and specificity, and antigen panels need standardizing. By screening an Echinococcus granulosus cDNA library with IgG1 from patients with CE, we identified E. granulosus thioredoxin peroxidase (EgTPx). Although IB and ELISA achieved the same specificity (92%), ELISA showed higher sensitivity than IB (83% versus 42%) in determining total immunoglobulin G (IgG) specific to EgTPx in CE sera. The percentage of total IgG- and IgG1-positive sera in ELISA was equally distributed in patients with active, transitional, and inactive disease. Conversely, the percentages of IgG4-positive sera were significantly higher in sera from patients with active than inactive disease (P = 0.03). Our data suggest that adding this highly specific recombinant antigen to the standard diagnostic panel of antigens used in ELISA would increase diagnostic sensitivity. Antibodies specific to EgTPx are of potential interest in the host-parasite relationship.
    Diagnostic Microbiology and Infectious Disease 04/2008; 60(3):279-85. DOI:10.1016/j.diagmicrobio.2007.10.004 · 2.57 Impact Factor